StemCell Therapy

Stem Cells - Dr,Awni Hanandeh and Dr.Hanan Jarrar
Bone Marrow from iliac Crest.

By: Zaid

The rest is here:
Stem Cells - Dr,Awni Hanandeh and Dr.Hanan Jarrar - Video

Rheumatoid arthritis | umbilical cord stem cells for ra
http://www.arthritistreatmentcenter.com Another type of stem cell that could hold potential for rheumatoid arthritis treatment... next Umbilical cord stem cells may be useful in the treatment...

By: Nathan Wei

Read the rest here:
Rheumatoid arthritis | umbilical cord stem cells for ra - Video

Los Angeles, CA (PRWEB) May 30, 2014

MetroMD Institute of Regenerative Medicine, a clinic that specializes in HGH and stem cell therapy, introduces an advanced cosmetic regeneration therapy that makes use of CO2 Fractional Laser System and highly efficient DOT to cure age-related skin problems, sun tanning, improve texture and laxity.

All within minimum discomfort, the Co2 Fractional Laser treatment helps in: 1.Reversing the appearance of aged and sun-damaged skin 2.Improving texture and elasticity of the skin 3.Smoothing Wrinkles 4.Reducing the acne and other scar marks

What does DOT Therapy Do?

Sun can wreak havoc to sensitive skin. Now, for ones who need to spend hours under the sun and suffer from wrinkles, discoloration, sun-spots, or lack of skin elasticity, or all of the above, the MetroMD DOT Therapy brings in a chance to alleviate individuals from all these problems. Persons with scars resulting from acne or other skin conditions and injuries can also benefit from this procedure.

One can restore skins youthful appearance with the DOT Therapy even within a one-hour sitting at the doctors office, says Dr Alex Martin, MD and the cosmetic regeneration specialist at MetroMD. While the aging process cannot be stopped, with proper care you can maintain your rejuvenated skins appearance for many years!

MetroMDs therapy is FDA approved and helps people feel younger and revitalized again. Patients seeking a cosmetic treatment in MetroMD, however, will have to go through a complete medical examination to ascertain if their body is suitable for the treatment.

Dr. Martin also said that to make the treatment accessible to more men and women, MetroMD have decided to offer the advanced cosmetic skin regeneration therapy at an exciting price. In addition, there are several charitable trusts that MetroMD has collaborated with in making their advanced therapies available to all at incredibly reduced prices!

About MetroMD

MetroMD is a prominent research institute of regenerative medicine based out of Los Angeles. The institute uses the latest medical technologies and has a highly qualified team to treat hundreds of patients who approach them for non-invasive and painless treatment. Involved in the field of cellular therapy for many years, Dr. Martins cosmetic akin and cellular regeneration therapy team renders complete pre and post treatment help.

See the original post:
MetroMDs Advanced Regenerative Therapy Set to Counter Aging; Interesting Price-sharing Model to Make Cosmetic ...

Miami (PRWEB) May 30, 2014

GlobalStemCellsGroup.com will host the First International Symposium on Stem Cell Research in Buenos Aires, Argentina Oct. 2, 3 and 4. The symposium will provide an opportunity to showcase advancements in stem cell research and therapies on a global level and establish a dialogue among the worlds leading stem cell experts. Pioneers and luminaries in stem cell medicine will be featured speakers as well as accomplished guests prepared to share their knowledge and experience in their individual medical specialties.

Regenerative medicine as a field is still in its infancy, and Global Stem Cells Group President and CEO Benito Novas believes it is time to clear up old misconceptions and change outdated attitudes by educating people on the wide range of illnesses and injuries stem cell therapies are already treating and curing. The first step, Novas says, is establishing a dialogue between researchers and practitioners in order to move stem cell therapies from the lab to the physicians office.

Our objective is to open a dialogue among the worlds medical and scientific communities in order to advance stem cell technologies and translate them into point-of-care medical practices, Novas says. Our mission is to bring the benefits of stem cell therapies to the physicians office for the benefit and convenience of the patient, safely and in full compliance with the highest standard of care the world has to offer.

An interdisciplinary team of leading international stem cell experts will provide a full day of high-level scientific lectures aimed at medical professionals.

Among the growing list of speakers are some of the worlds most prominent authorities on stem cell medicine including:

The objective of Global Stem Cell Groups international symposium is to educate the public and the medical community, and at the same time establish a dialog between physicians, scientists, biotech companies and regulatory agencies in order to advance stem cell technologies so they can be used to benefit people who need them.

Global Stem Cells Group is also joining forces with some of the most prestigious regenerative medicine conferences in South America including:

Stem cell therapies are revolutionizing the anti-aging aesthetics industry while offering new hope for sufferers of serious chronic debilitating diseases

For more information on the Global Stem Cell Group First International Symposium on Stem Cells and Regenerative Medicine and the events lineup of speakers, visit the Global Stem Cells Symposium website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

Read more here:
Global Stem Cells Group to Host the First International Symposium on Stem Cells and Regenerative Medicine in Buenos ...

Miami, FL (PRWEB) May 31, 2014

Global Stem Cells Group, its subsidiary Stem Cell Training, Inc. and Bioheart, Inc. have announced plans to conduct a two-day, hands-on intensive stem cell training course at the Servet CordnVida Clinic Sept. 27 and 28 in Santiago, Chile. The Adipose Derived Harvesting, Isolation and Re-integration Training Course, will follow the Global Stem Cells Group First International Symposium on Stem Cells and Regenerative Medicine at the Santiago InterContinental Hotel Sept. 26, 2014.

Global Stem Cells Group and the Servet CordnVida Stem Cell Bank Clinic of Chile are co-organizing the symposium, designed to initiate a dialogue between researchers and practitioners and share the expertise of some of the worlds leading experts on stem cell research and therapies.

Servet CordnVida is a private umbilical cord blood bank that harvests and stores the hematopoietic-rich blood stem cells found in all newborns umbilical cords after birth. The hematopoietic tissue is responsible for the renewal of all components of the blood (hematopoiesis) and has the ability to regenerate bone marrow and restore depressed immune systems.

Umbilical (UCB) stem cells offer a wealth of therapeutic potential because they are up to 10 times more concentrated than bone marrow stem cells. In addition, UCB cells have a generous proliferative capacity with therapeutic potential that is very similar to embryonic stem cells, without the ethical debate associated with embryonic stem cell research and use.

UCB cells are the purest adult stem cells available, coming from newborns who have not been exposed to disease or external damage. Many parents today are utilizing cord banks like Servet CordnVida to store their newborns UCB cells safely for future medicinal use if the need arises.

Global Stem Cells Group and Servet CordnVida represent a growing global community of committed stem cell researchers, practitioners and investors whose enthusiasm is a direct result of the hundreds of diseases and injuries that stem cell therapies are curing every day. Global Stem Cell Groups First International Symposium on Stem Cell Research and Regenerative Medicine will host experts from the U.S., Mexico, Greece, Hong Kong and other regions around the globe who will speak on the future of regenerative medicine and share experiences in their field of specialty. The Global Stem Cells Group is hoping the symposium will open lines of communication and cooperation, explore new and exciting techniques in stem cell therapies, and create an environment of education and learning.

For more information on the symposium and the lineup of guests and speakers already confirmed, visit the First International Stem Cells and Regenerative Medicine website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

To learn more Global Stem Cells Group, visit http://www.stemcellsgroup.com, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About Global Stem Cells Group:

Read more from the original source:
Global Stem Cells Group to Hold Intensive, Two-day Training Course on Stem Cell Harvesting, Isolation and Re ...

Miami (PRWEB) May 31, 2014

Global Stem Cells Group and the Servet CordnVida Stem Cell Bank Clinic of Chile will be teaming up to organize the First International Symposium on Stem Cells and Regenerative Medicine in Santiago, Chile Sept. 26, 27 and 28. The three-day symposium will be followed by an intensive hands-on training course at the Servet Clinic for medical practitioners interested in learning techniques for harvesting stem cells for in-office medical therapies.

Symposium organizers plan to initiate a dialogue between researchers and practitioners to bridge the gap between bench scienceresearch science that is exclusively conducted in a lab settingand stem cell therapies delivered in the physicians office.

The first-of-its-kind conference will host some of the worlds leading experts on stem cell research and therapies. Servet CordnVida General Manager Mauricio Cortes, Ph.D. says that Santiago is the perfect launching pad for the event, as awareness and increasing demand for stem cell services has swept the South American countrys healthcare market over the past decade.

The use of human stem cells in medical therapies has attracted major scientific and public attention because stem cells are pluripotent, meaning they have the ability to differentiate into all body tissues, Cortes says. Knowing this, the possibilities for regenerating damaged or diseased tissue where no effective treatments existed before opens a new world of possibilities to patients and healthcare providers.

Were very excited to participate in this important conference.

Servet CordnVida is a private umbilical cord blood bank that harvests and stores the hematopoietic-rich blood stem cells found in all newborns umbilical cords after birth. The hematopoietic tissue is responsible for the renewal of all components of the blood (hematopoiesis) and has the ability to regenerate bone marrow and restore depressed immune systems.

Umbilical (UCB) stem cells offer a wealth of therapeutic potential because they are up to 10 times more concentrated than bone marrow stem cells. In addition, UCB cells have a generous proliferative capacity with therapeutic potential that is very similar to embryonic stem cells, without the ethical debate associated with embryonic stem cell research and use.

Perhaps most significant is the fact that UCB cells are the purest adult stem cells available, coming from newborns who have not been exposed to disease or external damage. Many parents today are utilizing cord banks like Servet CordnVida to store their newborns UCB cells safely for future medicinal use if the need arises.

Thanks to advances in stem cell science, we can preserve an infants stem cells at birth and store them safely for his or her future, says CordnVida Director Javier Sez. Hopefully, this symposium will be the first of many like it in the future of regenerative medicine, because the more we discuss what we know about the power of stem cells to heal, the closer we get to sparing our patients from needless suffering when the cure is right before us.

Read this article:
Global Stem Cells Group Teams With CordnVida Servet Stem Cell Bank and Clinic to Organize the First International ...

The gap between stem cell research and regenerative medicine just became a lot narrower, thanks to a new technique that coaxes stem cells, with potential to become any tissue type, to take the first step to specialization. It is the first time this critical step has been demonstrated in a laboratory.

University of Illinois researchers, in collaboration with scientists at Notre Dame University and the Huazhong University of Science and Technology in China, published their results in the journal Nature Communications.

"Everybody knows that for an embryo to form, somehow a single cell has a way to self-organize into multiple cells, but the in vivo microenvironment is not well understood," said study leader Ning Wang, a professor of mechanical science and engineering at the U. of I. "We want to know how they develop into organized structures and organs. It doesn't happen by random chance. There are biological rules that we don't yet understand."

During fetal development, all the specialized tissues and organs of the body form out of a small ball of stem cells. First, the ball of generalized cells separates into three different cell lines, called germ layers, which will become different systems of the body. This crucial first step has eluded researchers in the lab. No one has yet been able to induce the cells to form the three distinct germ layers, in the correct order -- endoderm on the inside, mesoderm in the middle and ectoderm on the outside. This represents a major hurdle in the application of stem cells to regenerative medicine, since researchers need to understand how tissues develop before they can reliably recreate the process.

"It's very hard to generate tissues or organs, and the reason is that we don't know how they form in vivo," Wang said. "The problem, fundamentally, is that the biological process is not clear. What is the biological environment that controls this, so they can become more organized and specialized?"

Wang's team demonstrated that not only is it possible for mouse embryonic stem cells to form three distinct germ layers in the lab, but also that achieving the separation requires a careful combination of correct timing, chemical factors and mechanical environment. The team uses cell lines that fluoresce in different colors when they become part of a germ layer, which allows the researchers to monitor the process dynamically.

The researchers deposited the stem cells in a very soft gel matrix, attempting to recreate the properties of the womb. They found that several mechanical forces played a role in how the cells organized and differentiated -- the stiffness of the gel, the forces each cell exerts on its neighbors, and the matrix of proteins that the cells themselves deposit as a scaffolding to give the developing embryo structure.

By adjusting the mechanical environment, the researchers were able to observe how the forces affected the developing cells, and found the particular combination that yielded the three germ layers. They also found that they could direct layer development by changing the mechanics, even creating an environment that caused the layers to form in reverse order.

Now, Wang's group is working to improve their technique for greater efficiency. He hopes that other researchers will be able to use the technique to bridge the gap between stem cells and tissue engineering.

"It's the first time we've had the correct three-germ-layer organization in mammalian cells," Wang said. "The potential is huge. Now we can push it even further and generate specific organs and tissues. It opens the door for regenerative medicine."

The rest is here:
Researchers see stem cells take key step toward development: A first

PUBLIC RELEASE DATE:

30-May-2014

Contact: Liz Ahlberg eahlberg@illinois.edu 217-244-1073 University of Illinois at Urbana-Champaign

CHAMPAIGN, Ill. The gap between stem cell research and regenerative medicine just became a lot narrower, thanks to a new technique that coaxes stem cells, with potential to become any tissue type, to take the first step to specialization. It is the first time this critical step has been demonstrated in a laboratory.

University of Illinois researchers, in collaboration with scientists at Notre Dame University and the Huazhong University of Science and Technology in China, published their results in the journal Nature Communications.

"Everybody knows that for an embryo to form, somehow a single cell has a way to self-organize into multiple cells, but the in vivo microenvironment is not well understood," said study leader Ning Wang, a professor of mechanical science and engineering at the U. of I. "We want to know how they develop into organized structures and organs. It doesn't happen by random chance. There are biological rules that we don't yet understand."

During fetal development, all the specialized tissues and organs of the body form out of a small ball of stem cells. First, the ball of generalized cells separates into three different cell lines, called germ layers, which will become different systems of the body. This crucial first step has eluded researchers in the lab. No one has yet been able to induce the cells to form the three distinct germ layers, in the correct order endoderm on the inside, mesoderm in the middle and ectoderm on the outside. This represents a major hurdle in the application of stem cells to regenerative medicine, since researchers need to understand how tissues develop before they can reliably recreate the process.

"It's very hard to generate tissues or organs, and the reason is that we don't know how they form in vivo," Wang said. "The problem, fundamentally, is that the biological process is not clear. What is the biological environment that controls this, so they can become more organized and specialized?"

Wang's team demonstrated that not only is it possible for mouse embryonic stem cells to form three distinct germ layers in the lab, but also that achieving the separation requires a careful combination of correct timing, chemical factors and mechanical environment. The team uses cell lines that fluoresce in different colors when they become part of a germ layer, which allows the researchers to monitor the process dynamically.

The researchers deposited the stem cells in a very soft gel matrix, attempting to recreate the properties of the womb. They found that several mechanical forces played a role in how the cells organized and differentiated the stiffness of the gel, the forces each cell exerts on its neighbors, and the matrix of proteins that the cells themselves deposit as a scaffolding to give the developing embryo structure.

Read the original post:
For the first time in the lab, researchers see stem cells take key step toward development

Phil Reyes, one of the Parkinson's patients in Summit 4 Stem Cell, urges California's stem cell agency to support its research.

A potentially groundbreaking trial to treat spinal cord injuries with tissue grown from human embryonic stem cells will resume, after being funded by the California's stem cell agency.

The California Institute for Regenerative Medicine's governing committee approved without opposition a $14.3 million award to Asterias Biotherapeutics of Menlo Park. Asterias is taking over from Geron, which stopped clinical trials in November, 2011. Geron, also of Menlo Park, said it discontinued the trials for business reasons. Asterias is a subsidiary of Alameda-based BioTime.

Patients will be given transplants of neural tissue grown from the embryonic stem cells. The hope is that the cells will repair the severed connections, restoring movement and sensation below the injury site.

CIRM also unanimously approved a $5.6 million grant for another potential breakthrough: a clinical trial by Sangamo Biosciences of Richmond, Calif, to cure HIV infection with gene therapy. The trial is now in Phase II. Immune cells are taken from the patient and given a mutant form of a gene that HIV uses to get inside the cells. The mutated gene resists infection. The genetically altered cells are then given back to the patient.

Approval of both grants had been expected, as staff reports had recommended their approval. The agency met in San Diego.

In addition CIRM's Independent Citizens Oversight Committee funded $16.2 million in grants to bring three stem cell researchers to California. That vote was more contentious, with some committee members arguing that it made no sense to bring more scientists to California without a specific need. In addition, they argued that CIRM's main emphasis needs to be on funding clinical trials.

Member Jeff Sheehy said that bringing the scientists to California doesn't create more scientific capacity. However, a vote to deny funding failed, and a subsequent vote to approve funding passed.

CIRM is projected to run out of its $3 billion in bond funding by 2017, and supporters of the public agency are considering asking California voters for more money.

Also appearing at the CIRM meeting were advocates of funding a stem cell-based therapy for Parkinson's disease. The therapy, which may be approved in 2015 for a clinical trial, uses artificial embryonic stem cells called induced pluripotent stem cells grown from the patient's own skin cells. The group, Summit 4 Stem Cell, plans to ask for funding to help with the trial in the near future.

Go here to read the rest:
Spinal cord, HIV stem cell treatments funded

By Joel Ceausu, May 28th, 2014

An East End Montreal hospital is home to a new national network on regenerative medicine and cell therapy research. CellCAN will be based at Maisonneuve-Rosemont Hospital and directed by renowned cell therapy researcher Dr. Denis Claude Roy. The objective is to unite efforts of researchers, clinicians, funders, industry, charities, government members, patient representatives and the public. Specifically, CellCAN will promote exchanges, cooperation, partnership development and innovation in regenerative medicine and cell therapy, explained Roy. As the hub of a network of cell therapy centers and labs in Toronto, Ottawa, Quebec City, Edmonton, and Vancouver, CellCAN will propel Canadian stem cell research and clinical development forward thanks to a $3 million grant over four years. Discoveries in stem cell research make their way to clinical trials bringing researchers closer to new treatments for patients with cancer, diabetes, cardiovascular and ocular diseases, neurological and blood disorders and other health issues. Regenerative cell therapies have almost unlimited possibilities, said Roy, director of the cellular therapy laboratory at Maisonneuve-Rosemonts research centre. This will transform the nature of medicine and have significant impact on our health care systems. The Universit de Montral-affiliated hospital in Rosemont is an internationally recognized leader in hematology-oncology, stem cell transplants, ophthalmology, nephrology and kidney transplants. The funds come from the federally financed Networks of Centres of Excellence, Maisonneuve-Rosemont Foundation, Ronald and Herbert Black, and various organizations across Canada.n

Click here to see the full newspaper. Updated on May 28, 2014

Read the original:
East End home for cell network

Dr George Cotsarelis: Advances in Understanding Androgenetic Alopecia
Presented at the 8th World Congress for Hair Research (2014) in Jeju Island, South Korea. Abstract Summary: We originally localised hair follicle stem cells to the mouse and hair follicle...

By: Scientific Event Horizon

See original here:
Dr George Cotsarelis: Advances in Understanding Androgenetic Alopecia - Video

BBC News Researchers try to develop 3D printing of body parts
Researchers at the University Medical Centre Utrecht are experimenting using stem cells in 3D bio-printing. It is hoped one day the technology could make it possible to print replacement body...

By: Eric Turner

See the rest here:
BBC News Researchers try to develop 3D printing of body parts - Video

Stem Cells - Dr.Awni Hanandeh and Dr.Hanan Jarrar
Bone Marrow Aspiration from (Tibia)

By: Zaid

Read the original post:
Stem Cells - Dr.Awni Hanandeh and Dr.Hanan Jarrar - Video

Block GmbH Centre for Living Cell Therapy
The fresh cell therapy/stem cell therapy is always a full body treatment. The improvement of the function of individual organs also affects all other organs positively.

By: VIPiChannel

Continue reading here:
Block GmbH Centre for Living Cell Therapy - Video

PUBLIC RELEASE DATE:

28-May-2014

Contact: Robert Miranda cogcomm@aol.com Cell Transplantation Center of Excellence for Aging and Brain Repair

Tampa, Fla. (May 28, 2014) To be suitable for medical transplantation, one idea is that human embryonic stem cells (hESCs) need to remain "undifferentiated" i.e. they are not changing into other cell types. In determining the best way to culture hESCs so that they remain undifferentiated and also grow, proliferate and survive, researchers have used blood cell "feeder-layer" cultures using animal-derived feeder cells, often from mice (mouse embryonic fibroblasts [MEFs]). This approach has, however, been associated with a variety of contamination problems, including pathogen and viral transmission.

To avoid contamination problems, a Brazilian research team has investigated the use of human menstrual blood-derived mesenchymal cells (MBMCs) as feeder layers and found that "MBMCs can replace animal-derived feeder systems in human embryonic stem cell culture systems and support their growth in an undifferentiated stage."

The study will be published in a future issue of Cell Medicine, but is currently freely available on-line as an unedited early e-pub at: http://www.ingentaconnect.com/content/cog/cm/pre-prints/content-CM1019silvadosSantos.

"Human embryonic stem cells present a continuous proliferation in an undifferentiated state, resulting in an unlimited amount of cells with the potential to differentiate toward any type of cell in the human body," said study corresponding author Dr. Regina Coeli dos Santos Goldenberg of the Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro. "These characteristics make hESCs good candidates for cell based therapies."

Feeder-layers for hESCs comprised of MEFs have been efficiently used for decades but, because of the clinical drawbacks, the authors subsequently experimented with human menstrual blood cells as a potential replacement for animal-derived feeder-layers, not only for negating the contamination issues, but also because human menstrual blood is so accessible. MBMCs are without ethical encumbrances and shortages, nor are they difficult to access - a problem with other human cells, such as umbilical cord blood cells, adult bone marrow cells or placenta cells.

"Menstrual blood is derived from uterine tissues," explained the researchers. "These cells are widely available 12 times a year from women of child-bearing age. The cells are easily obtained, possess the capability of long-term proliferation and are clinically compatible with hESCs-derived cells."

The researchers found that their culture system using MBMCs as a feeder-layer for hESCs are the "closest and more suitable alternative to animal-free conditions for growing hESCs" and a "good candidate for large-expansion of cells for clinical application." They also found no difference in growth factor expression when comparing the use of growth factors in both the standard feeder system using animal cells and the feeder system they tested using hESCs.

Read more here:
Brazilian researchers find human menstrual blood-derived cells 'feed' embryonic stem cells

SINGAPORE: Australia-based stem cell therapy firm Mesoblast has announced plans to accelerate commercial manufacturing operations in Singapore.

This is to prepare for new product launches in the United States and other major markets over the next couple of years.

Its existing operations in Singapore include making stem cell products for clinical trials under its contract with its partner, pharmaceutical company Lonza.

One of its key products still awaiting full approval is Prochymal, which Mesoblast says can help to more than double the survival rate of patients suffering from complications after receiving tissue transplants from donors -- known as graft versus host disease.

The global stem cell market is expected to grow at an average annual rate of 12 per cent between 2011 and 2016 to reach more than S$8 billion by 2016.

Mesoblast said commercial manufacturing requires a much larger capacity and operations must be scaled-up to meet regulatory demands.

Silviu Itescu, chief executive at Mesoblast, said: "We are now in a phase of making more investments in order to get our processes to commercial scale. That anticipates successful commercial launches.

"If we're successful in that over the next 18-24 months, then we're going to leverage the investment in our commercial facilities to be able to build up and prepare for launching of much larger opportunities in cardiovascular medicine, orthopaedics and diseases of immunity and inflammation which would require purpose-built facilities."

Here is the original post:
Mesoblast to accelerate operations in S'pore

Johns Hopkins #39; Erika Matunis on Stem Cells and Why Science Must Stay Healthy
Stem cell biologist Erika Matunis on why fruit flies are great system for cell biology, stem cells and women. http://www.hopkinsmedicine.org/institute_basic_...

By: Johns Hopkins Medicine

View post:
Johns Hopkins' Erika Matunis on Stem Cells and Why Science Must Stay Healthy - Video

Meat Made from Stem Cells!
https://www.youtube.com/channel/UC1N85MiTQ-N0gsI3XBCCYbw?sub_confirmation=1 Made with some breadcrumbs, egg, and 20000 lab-grown cow muscle cells, the world...

By: Real Thing TV

Read the original here:
Meat Made from Stem Cells! - Video

CIRM Movie on Diabetes for Viacyte
ViaCyte, Inc., a leader in the emerging field of regenerative medicine, is headquartered in San Diego, California. ViaCyte #39;s innovative product is based on the differentiation of stem cells...

By: Viacyte

Read this article:
CIRM Movie on Diabetes for Viacyte - Video

DMD Mauritian Boy Basic Evaluation Pre-Stem Cells
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

Read the rest here:
DMD Mauritian Boy Basic Evaluation Pre-Stem Cells - Video